The AbDrop™ platform uses microfluidic technology to encapsulate individual plasma cells in droplets. This high-throughput approach enables researchers to screen millions of plasma B cells in a single day.
Workflow Highlights:
One Day: Millions of B cells screened for antibody-producing potential.
One Week: High-throughput sequencing and data analysis.
One Month: Purified antibodies with validated activity.
One Screening Cycle: Hundreds of naturally paired heavy and light chains obtained.
This platform reduces reagent consumption, integrates multiple development steps, and increases precision. Researchers can identify unique and functional antibodies faster, ensuring the discovery of effective therapeutic candidates.
Cyagen’s HUGO-Ab™ Mice: Cutting-Edge Human Antibody Models
The HUGO-Ab™ mice are genetically engineered to produce fully human antibodies. Using proprietary TurboKnockout® ES technology, these mice achieve stable phenotypic and functional outcomes without requiring humanization steps. Advantages of HUGO-Ab™ Mice:
High Affinity and Low Immunogenicity: Antibodies derived from these mice exhibit strong target binding and minimal immune response, critical for safety and efficacy.
Proven Performance: Recognized by leading institutions, HUGO-Ab™ mice have consistently delivered high-quality therapeutic antibodies.
Enhanced Diversity: These mice include the full spectrum of human antibody heavy and light chain genes, increasing the diversity of potential antibody candidates.
Our High-throughput Fully Human Antibody Discovery Platform integrates Cyagen’s HUGO-Ab™ mice with Biointron’s AbDrop™ microdroplet-based single B cell screening. This powerful combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months. Learn more about the service here.
